Relationship between management of hyperthyroidism and course of the ophthalmopathy

Journal of Endocrinological Investigation

Volumn 27, Issue 3, 2004, Pages 288-294

  Bartalena, Luigi ^a   Tanda, M L ^a   Piantanida, E ^a   Lai, A ^a   Pinchera, A ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Glucocorticoids; Graves' disease; Graves' ophthalmopathy; Methimazole; Radioiodine therapy; Smoking; Thyroidectomy

Indexed keywords

ANTITHYROID AGENT; GLUCOCORTICOID; LEVOTHYROXINE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE DERIVATIVE; THYROTROPIN; THYROTROPIN RECEPTOR;

ARTICLE; AUTOIMMUNE DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; HUMAN; HYPERTHYROIDISM; PATHOGENESIS; RETROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

EID: 2342543998     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345279     Document Type: Article

References (50)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168-99.
2. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 1989, 120: 473-8.
3. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1995, 42: 42-50.
4. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid 1992, 2: 171-8.
5. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990, 70: 1518-24.
6. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997, 7: 369-75.
7. Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibody to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991, 324: 947-53.
8. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996, 334: 220-4.
9. Glinoer D, de Nayer P, Bex M, and the Belgian Collaborative Group on Graves' Disease. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' disease treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001, 144: 475-93.
10. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 1989, 121 (Suppl. 2): 185-9.
11. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990, 150, 1098-101.
12. Solem JH, Segaard E, Ytteborg J. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med Scand 1979, 205: 111-4.
13. Aranow H Jr, Day RM. Management of thyrotoxicosis in patients with ophthalmopathy: antithyroid regimen determined primarily by ocular manifestations. J Clin Endocrinol Metab 1965, 25: 1-10.
14. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998, 338: 73-8.
15. Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves' disease. JAMA 1982, 247: 2136-8.
16. Marcocci C, Bartalena L, Pinchera A. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998, 21: 468-71.
17. Weetman AP, Harrison BJ. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998, 21: 472-5.
18. Catz B, Perzik SL. Subtotal vs total surgical ablation of the thyroid, malignant exophthalmos and its relation to remnant thyroid. In: Cassano C, Andreoli M eds. Current topics in thyroid research. New York: Academic Press. 1983, 1183-8.
19. Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery 1996, 120: 1020-4.
20. Fernandez-Sanchez JR, Rosell Pradas J, Carazo Martinez O, et al. Graves' ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. Br J Surg 1993, 80: 1134-6.
21. Patwardhan NA, Moront M, Rao S, Rossi S, Braverman LE. Surgery still has a role in Graves' hyperthyroidism. Surgery 1993, 114: 1108-13.
22. Abe Y, Sato H, Noguchi M, et al. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves' disease. World J Surg 1998, 22: 714-7.
23. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989, 87: 70-3.
24. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992, 326: 1733-8.
25. Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves' ophthalmopathy is not influenced by near-total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999, 51: 503-8.
26. Bartalena L, Marcocci C, Pinchera A. Radioiodine therapy and Graves' ophthalmopathy. In: Rapoport B, McLachlan SM eds. Graves' Disease: pathogenesis and treatment. Boston: Kluwer Academic Publishers. 2000, 279-92.
27. Gorman CA. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 1995, 80: 340-2.
28. Pinchera A, Bartalena L, Marcocci C. Radioiodine may be bad for Graves' ophthalmopathy, but.... J Clin Endocrinol Metab 1995, 80: 342-5.
29. Werner SC, Coelho B, Quimby EH. Ten year results of I-131 therapy in hyperthyroidism. Bull NY Acad Sci 1957, 33: 783-806.
30. Hamilton HE, Schutz RO, DeGowil EL. The endocrine eye lesion in hyperthyroidism. Arch Intern Med 1960, 105: 675-85.
31. Hamilton RD, Mayberry VE, McConahey WM, Hanson KC. Ophthalmopathy of Graves' disease: a comparison between patients treated surgically and patients treated with radioiodine. Mayo Clin Proc 1967, 42: 812-8.
32. Pequegnat EP, Mayberry WE, McConahey WM, Wyse EP. Large doses of radioiodine in Graves' disease: effects on ophthalmopathy and long-acting thyroid stimulator. Mayo Clin Proc 1967, 42: 802-11.
33. Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G, Utiger RD. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinol Metab 1967, 27: 582-93.
34. Hetzel BS, Mason EK, Kwan WH. Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis. Australas Ann Med 1967, 17: 307-11.
35. Aron-Rosa D, Pérez R, Abitbol Y. Malignant exophthalmos after iodine-131 treatment. Mod Probl Ophthalmol 1973, 14: 432-4.
36. Calissendorf BM, Soderstrom M, Alveryd A Ophthalmopathy and hyperthyroidism: a comparison between patients receiving different antithyroid treatments. Acta Ophthalmol 1986, 64: 698-703.
37. Vestergaard H, Laurberg P. Radioiodine and aggravation of ophthalmopathy. Lancet 1989, 2: 47.
38. Barth A, Probst P, Burgi H. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine. J Endocrinol Invest 1989, 14: 209-12.
39. Kung AWC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994, 79: 542-6.
40. Manso PG, Furlanetto RP, Wolosker AMB, Paiva ER, de Abreu MT, Maciel RMB. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism. Thyroid 1998, 8: 49-52.
41. Spitzweg C, Rossmuller B, Heufelder AE. Radioiodine therapy and Graves' ophthalmopathy. Thyroid 1998, 8: 1193.
42. Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989, 321: 1349-52.
43. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994,130: 494-7.
44. Vàzquez-Chàvez C, Nishimura Megura E, Espinosa Said L, Delgado Falfari A, Sàinz de Viteri M. Influencia del tratamento del hipertirodismo en el curso del exoftalmos. Rev Invest Clin 1992, 44: 241-7.
45. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998, 129: 632-5.
46. Bartalena L. Smoking and Graves' disease. J Endocrinol Invest 2002, 25: 402.
47. Karlsson AF, Dahlberg BA, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol (Copenh) 1989, 121 (Suppl. 2): 132-41.
48. Weetman A, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998, 49: 21-8.
49. DeGroot LJ. Radioiodine and the immune system. Thyroid 1997, 7: 259-64.
50. DeGroot LJ, Benjasuratwong Y. Evaluation of thyroid ablative therapy for ophthalmopathy of Graves' disease. Orbit 1996, 15: 187-96.